Mechanistically, treatment downregulated anti-apoptotic BCL-2 family proteins and promoted activation of pro-apoptotic pathways, thereby restoring apoptotic sensitivity in ATLL cells [80]. This evidence concerns the gene BCL2 and adult T-cell leukemia/lymphoma.